New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
05:58 EDTGILD, GMStocks with implied volatility movement; GM GILD
Stocks with implied volatility movement; General Motors (GM) 33, Gilead (GILD) 39 according to iVolatility.
News For GM;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
17:06 EDTGILDGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
16:26 EDTGMMajor automakers sued over allegedly 'deadly' keyless technology, Reuters says
A number of automakers have been named in a lawsuit alleging that keyless ignition technology can lead to "deadly" results due to carbon monoxide poisoning from cars left running under the belief that engines will automatically switch off, reports Reuters. Defendants include General Motors (GM), Ford (F), Fiat Chrysler (FCAU), Honda (HMC), Hyundai (HYMLF), Nissan (NSANY), Toyota (TM), Volkswagen (VLKAY), BMW (BAMXY), and Daimler's (DDAIF) Mercedes Benz, said Reuters. According to the plaintiffs, the carmakers had "actual knowledge" of the so-called risks and could have prevented 13 deaths and numerous injuries. Reference Link
13:42 EDTGMTrueCar says 'on plan' to hit 17.2M U.S. vehicle forecast for 2015
Subscribe for More Information
13:19 EDTGMTrueCar says daily auto sales pace up 0.9% for August, with 17.4M SAAR
Subscribe for More Information
August 25, 2015
19:34 EDTGILDExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
August 24, 2015
19:36 EDTGMGeneral Motors ends two-week strike in Brazil, Reuters says
Subscribe for More Information
17:50 EDTGMGeneral Motors denies 3944 of 4343 ignition switch claims
Subscribe for More Information
13:36 EDTGILDBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
09:45 EDTGMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTGMOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTGMGeneral Motors coverage resumed with an Underweight at Morgan Stanley
Subscribe for More Information
06:14 EDTGMGM recalling 59,474 2010 Chevrolet Cobalt vehicles
GM is recalling 59,474 2010 Chevrolet Cobalt vehicles manufactured January 4, 2010, to June 23, 2010. The affected vehicles may be equipped with an improperly routed Side-Impact Sensor wiring harness in the driver side front door. The misrouted wiring harness could cause an electrical short that disables the driver side curtain air bag. A disabled driver side roof-rail air bag will not deploy in the event of a crash necessitating deployment of that air bag, increasing the risk of injury to the driver.
August 23, 2015
18:23 EDTGMGM, Volkswagen slow production at Chinese factories, WSJ says
Auto manufacturers including General Motors (GM) and Volkswagen (VLKAY) appear to be running their Chinese factories at less than maximum capacity for the first time, reports the Wall Street Journal, citing industry data. The numbers suggest that a "bumpier ride" may be in store for multinationals that counted on Chinese demand, said the report. "The situation seems worse than that of 2008," remarked an engineer working at GM's Shanghai plant. Reference Link
August 21, 2015
06:46 EDTGMGM recalling 5,493 2014-2015 Chevrolet Impala vehicles
Subscribe for More Information
August 20, 2015
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
August 19, 2015
13:35 EDTGMGM investing C$12M for added Chevrolet Equinox production at Oshawa Assembly
GM Canada president and managing director Steve Carlisle announced that GM will invest C$12M to increase Chevrolet Equinox production on the Consolidated production line at Oshawa Assembly and for related changes in the body shop at CAMI Assembly. This further investment in Ontario-based production and supplier tools will help to meet strong North American customer demand for the Chevrolet Equinox. The investment extends plans for ongoing Oshawa Assembly Consolidated Line production to 2017. GM has invested approximately C$800M in its Oshawa and St. Catharines operations over the past 3 years and recently announced a further $800M investment in its CAMI operation in Ingersoll, Ontario.
August 18, 2015
16:50 EDTGMGM's future Buick production may shift to Europe, China, Reuters reports
According to two sources familiar with General Motors' plans, the majority of Buick vehicles sold in the United States after 2016 may be imported from China and Europe, Reuters reports. Reference Link
15:58 EDTGMGM's future Buick production may shift to Europe, China, Reuters reports
August 17, 2015
07:42 EDTGMNew Street-high target of $465 gives Tesla shares a charge
Shares of Tesla Motors (TSLA) are jumping after Morgan Stanley boosted its price target by $185 to $465, a new high among Wall Street analysts. The company is positioned to dominate as car sales shift to robot-driven and shared vehicles, the firm argues. SELLING MILES: Morgan Stanley analyst Adam Jonas raised his price target for Tesla Motors to $465 from $280, well above Friday's closing price of $243.15. Today, ten trillion vehicle miles are driven annually, with almost all of them delivered by "companies practicing a 100-year-old business model of human-driven, privately owned, internal-combustion vehicles," Jonas tells investors in a research note. General Motors (GM), Ford (F), Toyota (TM) and Honda (HMC) are among the publicly traded traditional carmakers. The market of selling cars is going through some fundamental changes, argues Jonas. He believes Tesla is "uniquely positioned" to dominate given its expertise in autonomous technology and networked machine learning. An app-based, on-demand mobility service could more than triple Tesla's potential revenues by 2029, the analyst estimates. He expects Tesla over the next 18 months to roll out formalized business plans on shared mobility, allowing the electric vehicle maker to sell miles in addition to cars. His new price target of $465 reflects Tesla's potential to lead the revolution of the shared mobility public transportation hyper-structure and more confidence around the commercial viability of Tesla Energy. ROBOT-DRIVEN: Jonas expects nearly all car sales to eventually shift from human-driven, individually-owned cars to robot-driven and shared cars. If Tesla wants to succeed on its mission of accelerating the world's transition to sustainable transport, the move to a shared mobility model is critical, he argues. All of Tesla's cars are electric, connected, and able to "learn" through over-the- air firmware updates at any time, which no other established automaker can claim today, Jonas writes. MARKET REACTION: Investors are buying into what Jonas is arguing. Shares of Tesla are up 5%, or $13.10, to $256.25 in pre-market trading. Over the past three months through Friday's close, the stock is down 2%.
August 16, 2015
15:44 EDTGMGeneral Motors to invest 'several million' in historic factory renovation
General Motors announced that the "historic" Durant-Dort Factory One will be converted into an archive and research center as part of a renovation project. GM will invest several million dollars to create a modern archive to house the automotive collection currently located at Kettering University. The archive and research center will occupy the first floor of the east wing of Factory One. GM plans to develop the second floor of the east wing into a meeting area for GM, community and educational groups to conduct STEM-related classes, seminars and, potentially, research. The high-bay area in the west wing of the facility will be renovated to house classic vehicles and other historical artifacts. Once plans are finalized and a general contractor is selected, work on the archive and other interior projects could begin in early 2016 with the project completed in 2017, according to GM. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use